Daniel Ek, who co-founded Spotify in 2006 and led it as CEO for nearly two decades, formally stepped back from that role effective January 1, 2026, becoming Executive Chairman while handing day-to-day leadership to two co-CEOs: Gustav Söderström, previously the company’s co-President and Chief Product and Technology Officer, and Alex Norström, previously co-President and Chief Business Officer. Spotify’s stock dropped when Ek first announced the transition plan in September 2025 — a common market reaction to a founder-CEO stepping back, even when the transition is planned well in advance and the incoming leadership team is deeply familiar with the business.
With more time freed up from Spotify’s daily operations, Ek has focused increasing attention on Neko Health, a health-tech startup he co-founded that operates clinics offering full-body scans — a single, roughly hour-long appointment combining multiple diagnostic technologies (including skin imaging, ECG heart monitoring, and body composition analysis) to screen for a wide range of potential health issues in one visit, rather than requiring separate appointments with multiple specialists. Neko Health announced on July 15, 2026 that it had raised $700 million in new funding, with the capital specifically earmarked to open clinics in New York City and other U.S. cities later in the year — its first major expansion beyond its existing European clinics.
A Founder Explicitly Choosing Where to Spend His Time
Ek’s move from Spotify CEO to Executive Chairman, paired with his growing public focus on Neko Health, is a genuinely explicit example of a highly successful founder deliberately choosing to redirect his own time toward a newer venture rather than treating his original company as a permanent, full-time commitment indefinitely. Unlike founders who are pushed out or forced into a transition by a board or investors, Ek’s own transition was announced on his own terms, with a clear successor structure already in place well before the actual handover date.
What Neko Health’s Scan Actually Involves
Neko Health’s core product is worth understanding in concrete terms, since it’s a genuinely novel format for preventive healthcare: a single appointment lasting roughly an hour that combines multiple diagnostic technologies — full-body skin imaging to screen for early signs of skin cancer, an ECG to check heart rhythm, and body composition analysis — into one visit, with results delivered and explained the same day. The pitch is direct: catching potential health issues years earlier than a person might otherwise discover them through routine, infrequent doctor visits, delivered through a retail-like clinic experience rather than a traditional hospital or specialist setting. The $700 million raise specifically funds Neko’s first serious push into the US healthcare market, a considerably more complex regulatory and insurance environment than the European markets where it first operated.
What This Means for Philippine Founders
Ek’s transition is a useful, real-world model for any Philippine founder eventually planning their own step back from day-to-day operations at a company they built: naming a clear leadership structure (in Ek’s case, two co-CEOs splitting product/technology and business responsibilities) well in advance of the actual handover, rather than leaving the transition timeline or structure ambiguous, gives both the company and outside stakeholders real confidence the business will keep running smoothly. Neko Health’s $700 million raise and U.S. expansion is also a concrete signal for Philippine health-tech founders that diagnostic and preventive-health startups — not just AI chatbots or treatment-focused products — remain a genuinely well-funded category globally, with a name as prominent as Ek’s own lending real additional credibility to the broader preventive-health-tech space. It’s also a reminder that a founder’s reputation and network built at one company can meaningfully de-risk fundraising for a completely unrelated second venture — investors backing Neko Health’s $700 million round were, in part, betting on Ek’s own two-decade track record building and scaling Spotify, not solely on Neko’s own still-developing track record in a genuinely new industry for him. Whether that reputation-driven trust ultimately proves warranted will depend on execution specific to healthcare — a far more heavily regulated and higher-stakes industry than music streaming, where Ek’s original expertise was built, and one where past success in a different sector offers no guarantee of a smooth transition. Philippine founders considering a similar pivot into an entirely new industry after an initial success should weigh that same gap honestly: the credibility and capital a strong track record buys is real, but it doesn’t substitute for the domain-specific expertise a genuinely different regulated industry actually requires. Ek has reportedly built out a dedicated leadership team at Neko Health specifically to supply the medical and regulatory expertise his own background in music streaming never required, rather than assuming his Spotify experience alone would translate directly. That distinction between reputation-driven fundraising and execution-driven results is one worth keeping separate when evaluating any founder’s move into a genuinely new industry, especially in healthcare, where regulatory approval timelines and clinical trust are built on a fundamentally different, slower timeline than a consumer software product.
Share this article